Treatment of facial and axillary lupus miliaris with adalimumab

Ann Dermatol Venereol. 2024 Sep;151(3):103307. doi: 10.1016/j.annder.2024.103307. Epub 2024 Aug 23.

Authors

M Robert¹, M Le Moigne², B Cribier³, E Cassagnau⁴, S Barbarot²

Affiliations

¹ Dermatology, CHU, Nantes, France. Electronic address: marine.robert@ch-bretagne-atlantique.fr.
² Dermatology, CHU, Nantes, France.
³ Dermatology, CHU, Strasbourg, France.
⁴ Anatomical Pathology, CHU, Nantes, France.

PMID: 39180932
DOI: 10.1016/j.annder.2024.103307

No abstract available

Keywords: Anti TNF; Cutaneous granulomatosis; Lupus miliaris.

Publication types

Case Reports
Letter

MeSH terms

Adalimumab* / therapeutic use
Adult
Anti-Inflammatory Agents / therapeutic use
Axilla*
Facial Dermatoses / drug therapy
Female
Humans
Lupus Erythematosus, Cutaneous / drug therapy
Lupus Erythematosus, Cutaneous / pathology

Substances

Adalimumab
Anti-Inflammatory Agents